Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
GSK application for myeloma treatment accepted by EMA
(Sharecast News) - GSK announced on Friday that the European Medicines Agency (EMA) has accepted its marketing authorisation application for 'Blenrep', or belantamab mafodotin, in combination with bortezomib plus dexamethasone - 'BorDex', or pomalidomide plus dexamethasone - PomDex, for treating relapsed or refractory multiple myeloma. The FTSE 100 pharmaceutical giant said the EMA's Committee for Medicinal Products for Human Use (CHMP) would now begin the formal review process to recommend potential authorisation to the European Commission.
It said the application was supported by interim results from the phase three 'DREAMM-7' and 'DREAMM-8' trials, both of which achieved their primary endpoints by demonstrating statistically significant and clinically meaningful improvements in progression-free survival (PFS) for the Blenrep combinations compared to standard care treatments.
Specifically, the DREAMM-7 trial compared Blenrep combined with BorDex against daratumumab plus BorDex, while the DREAMM-8 trial evaluated Blenrep with PomDex versus bortezomib plus PomDex.
Although the trials also indicated a positive trend in overall survival (OS), GSK said that was not statistically significant at the interim analysis stage, with overall survival follow-up ongoing.
Additionally, the results showed clinically meaningful improvements across all secondary efficacy endpoints, including deeper and more durable responses compared to the standard care combinations.
The safety and tolerability profiles observed for the Blenrep combinations were consistent with the known profiles of the individual agents involved in the trials.
"Today's milestone reinforces the potential for Blenrep to redefine outcomes for patients with multiple myeloma at or after first relapse," said senior vice-president and global head of oncology research and development Hesham Abdullah.
"We are working to bring Blenrep to patients as quickly as possible given the high unmet need and the clinically robust effects of the Blenrep combinations in the DREAMM-7 and DREAMM-8 phase three head-to-head trials."
At 1214 BST, shares in GSK were down 0.81% at 1,517.62p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
